Of the 352 patients with advanced NSCLC who underwent Cobas EGFR Mutation Test or Oncomine Dx Target Test Multi CDx between January 2017 and March 2022, EGFR mutations were detected in 94 patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.